Finance

Lists
GYRE:NASDAQ
Gyre Therapeutics Inc
US$ ७.११
+१.५७%
(+०.११) 1D
US$ ७.११
०.००% (०.००)
After hours
Closed: अक्टोबर २, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GYRE...
Open
US$ ७.०९
High
US$ ७.३५
Low
US$ ७.०८
Mkt. cap
७५.३९ करोड
Avg. vol.
१.५१ लाख
Volume
१.६४ लाख
52-wk high
US$ ९.४२
52-wk low
US$ ५.४४
EPS
-US$ ०.२०
Beta
२.१८
Shares outstanding
१०.६० करोड
No. of employees
६२५
Open
US$ ७.०९
High
US$ ७.३५
Low
US$ ७.०८
Mkt. cap
७५.३९ करोड
Avg. vol.
१.५१ लाख
Volume
१.६४ लाख
52-wk high
US$ ९.४२
52-wk low
US$ ५.४४
EPS
-US$ ०.२०
Beta
२.१८
Shares outstanding
१०.६० करोड
No. of employees
६२५
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
२८ मिनेट पहिले
Will Raised EBITDA Guidance Change Garrett Motion Stock Narrative
The Motley Fool
The Motley Fool
·
४४ मिनेट पहिले
History Says Coca-Cola Stock Holds Up When the S&P 500 Falls
Business Insider
Business Insider
·
१३ घण्टा पहिले
The NYSE's Most Famous Floor Trader Says AI Can't Take His Job
About Gyre Therapeutics Inc
CEO-
Employees६२५
Founded१९९७
Headquartersविन्सटन-सलेम, नर्थ क्यारोलाइना, संयुक्त राज्य अमेरिका
Sector-
Websitegyretx.com
Analyst ratings
Based on 2 analysts giving stock ratings to GYRE in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for GYRE in the last 3 months.
Highest
Current US$ ७.११
US$ २०.०० (+१८१.२९%)
Average
US$ १९.०० (+१६७.२३%)
Lowest
US$ १८.०० (+१५३.१६%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert LeBoyer
Noble Financial
Buy
Reiterated
US$ २०.००
+१८१.३%
08/10/2026
Matthew Keller
H.C. Wainwright
Buy
Reiterated
US$ १८.००
+१५३.२%
08/07/2026
Roger Song
Jefferies
Buy
Initiated
US$ १६.००
+१२५%
10/10/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
३.०६ करोड
३.७२ करोड
२.४४ करोड
२.९१ करोड
Cost of goods sold
१६.२८ लाख
१७.४३ लाख
१२.२७ लाख
२२.०९ लाख
Cost of revenue
१६.२८ लाख
१७.४३ लाख
१२.२७ लाख
२२.०९ लाख
Research and development expenses
२३.६३ लाख
४८.१५ लाख
१.१५ करोड
१.९१ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१.९६ करोड
३.०५ करोड
२.४३ करोड
२.१६ करोड
Operating expense
२.२० करोड
३.५३ करोड
३.५८ करोड
४.०८ करोड
Total operating expenses
२.३६ करोड
३.७१ करोड
३.७० करोड
४.३० करोड
Operating income
६९.२६ लाख
१.२० लाख
-१.२६ करोड
-१.३९ करोड
Other non operating income
६.०४ लाख
-२३.११ लाख
२.४४ लाख
-८.११ लाख
EBT including unusual items
७६.२९ लाख
-६६.०० हजार
-१.८० करोड
-१.४४ करोड
EBT excluding unusual items
७६.३० लाख
-८.६४ लाख
-१.१६ करोड
-१.३९ करोड
Income tax expense
१६.९३ लाख
१३.०० लाख
५.४९ लाख
-१.६४ लाख
Effective tax rate
२२.१९%
-१,९६९.७०%
-३.०४%
१.१४%
Other operating expenses
-
-
-
-
Net income
३६.१० लाख
-१७.२३ लाख
-१.०३ करोड
-१.०६ करोड
Net profit margin
११.८१%
-४.६३%
-४२.१६%
-३६.४४%
Earnings per share
०.०३
०.०५
-
-
Interest and investment income
१.०० लाख
१३.४७ लाख
७.४३ लाख
७.४० लाख
Interest expense
-
-
-
-
Net interest expenses
१.०० लाख
१३.४७ लाख
७.४३ लाख
७.४० लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
७५.७५ लाख
८.१५ लाख
-१.१९ करोड
-१.२४ करोड
Gain or loss from assets sale
१.०० हजार
२.०० हजार
१६.०० हजार
२.०० हजार
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू